Attorney General Headshot

Attorney General Marty Jackley

Attorney General Seal

Attorney General Long Joins $33 Million Settlement with Pfizer Inc.

Attorney General Long Joins $33 Million Settlement with Pfizer Inc.  

PIERRE, S.D.-   Attorney General Larry Long announced today that he, along with 42 other Attorneys General, reached a $33 million dollar settlement with Pfizer Inc. related to the drug company’s alleged improper marketing of the antipsychotic drug Geodon.  In a complaint soon to be filed in court along with the settlement agreement, Long alleges that Pfizer engaged in unfair and deceptive practices when it marketed Geodon for off-label uses, which are uses that have not been approved by the U.S. Food and Drug Administration (FDA). Pfizer has agreed to change how it markets Geodon and has agreed not to promote “off-label” uses. The State of South Dakota will receive $433,833 as a result of this settlement.

Geodon is the brand name for the prescription drug ziprasidone. The drug has been approved by the FDA for treatment of schizophrenia in adults and for manic or mixed episodes of bipolar disorder in adults.  The complaint alleges that Pfizer promoted Geodon for a number of off-label uses, including pediatric use and use at dosage levels higher than had been approved by the FDA.  Although a physician is allowed to prescribe drugs for off-label uses, federal law prohibits pharmaceutical manufacturers from marketing their products for off-label uses.  

The settlement mandates that Pfizer shall:

  • Not make any false, misleading or deceptive claims regarding Geodon;
  • Not promote Geodon for off-label uses;
  • Not promote Geodon using selected symptoms of the FDA-approved  diagnoses unless certain disclosures are made regarding the approved diagnoses;
  • Post on its website a list of  physicians and related entities who receive payments from Pfizer until 2014;
  • Provide product samples of Geodon only to health care providers who have specialties that customarily treat patients who have diseases for which treatment with Geodon would be consistent with the product’s current labeling;
  • Register and post on a publicly accessible website certain Pfizer-sponsored clinical trials; and
  • Require its medical staff to be responsible for the identification, selection, approval and dissemination of scientific article reprints containing off-label information regarding Geodon, and that such information not be referred to or used in a promotional manner.

The settlement also mandates that for a nine-year time period (which extends beyond the patent term for Geodon), Pfizer shall require its medical staff, rather than its marketing staff, to have ultimate responsibility for developing and approving the medical content for all medical letters regarding Geodon.

For a six-year period, Pfizer must:

  • Disclose on its website information about grants it makes to health care providers, including continued medical education grants;
  • Not use grants to promote Geodon, or condition CME funding on Pfizer’s approval of speakers or program content; and
  • Contractually require continuing medical education providers to disclose Pfizer’s financial support of their programs and any financial relationship with faculty and speakers.